Citi analysts upgraded Insulet Corporation (NASDAQ:PODD) from Neutral to Buy, lowering the price target from $273.00 to $265.00. The analysts noted the substantial drop in valuation as the reason for the upgrade. Despite previous concerns about valuation, tough year-over-year comparisons, and GLP-1 impact, the 37% stock decline from its peak and 29% YTD decrease prompted the upgrade.

The new price target is based on a valuation range of 9-10 times the 2024 estimated EV/Revenue. Insulet's pending FDA application for its iPhone app, integration plans for Dexcom's G7 and Abbott's L2, and the ongoing Omnipod 5 launch in the U.K. and upcoming launch in Germany were also highlighted.